APOA4 ELISA kit
- Known as:
- APOA4 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- DL-APOA4-Ra
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- WDSTD
- Gene target:
- APOA4 ELISA kit
Related genes to: APOA4 ELISA kit
- Gene:
- APOA4 NIH gene
- Name:
- apolipoprotein A4
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 11q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-04-26
Related products to: APOA4 ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: APOA4 ELISA kit
- Autosomal dominant tubulointerstitial kidney disease (ADTKD) is a genetically heterogeneous disorder characterized by progressive chronic kidney disease, primarily affecting the tubules and interstitium. It results from pathogenic variants in several known genes, including UMOD, mucin-1 (MUC1), REN, APOA4, and others. Despite its clinical significance, ADTKD is often under-recognized due to nonspecific histopathological and clinical features and limited referral for genetic testing, which remains the gold standard for diagnosis. In addition, due to technical difficulties, genetic testing for ADTKD-MUC1 is not currently performed in multigene panels and cannot be obtained through whole exome or genome sequencing. Recent advances in kidney disease research underscore the critical role of comprehensive genetic testing in elucidating the molecular etiology of unsolved cases. However, challenges persist in the diagnosis of specific ADTKD subtypes, particularly those caused by pathogenic MUC1 pathogenic variants. This review provides a detailed analysis of the genetic basis, clinical presentation, and diagnostic approaches for ADTKD, with an emphasis on the limitations in current testing methodologies for ADTKD-MUC1. We further explore recent advancements in our understanding of ADTKD and highlight future directions for improving diagnostic accuracy and patient care through enhanced genetic testing technologies. - Source: PubMed
Publication date: 2026/05/22
Connaughton Dervla MArnaldi MonicaKidd Kendrah OBleyer Anthony J - Osteoarthritis (OA) pathogenesis involves dysregulated extracellular matrix (ECM) remodeling and inflammation. Apolipoprotein A4 (APOA4), while known for lipid metabolism, has an uncharacterized role in OA. - Source: PubMed
Publication date: 2026/05/11
Yao HaoyuLi YaLiang MiaoyangCao BixuanYang ShuoNing Rende - Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy associated with heterogeneous prognosis. Preoperative differentiation from adrenocortical adenoma (ACA) remains challenging, and no serum tumor marker has been established. We aimed to identify circulating protein biomarkers that distinguish ACC from ACA using a stepwise, multiplatform proteomics strategy. - Source: PubMed
Park Seung ShinSeo HoseokMoon Sun JoonJang Han NaLee Seung HunKim Su-JinLee Kyu EunHan DohyunKim Jung Hee - : Determining the cardiovascular cause of death, particularly distinguishing ischemic from congestive mechanisms, remains challenging in forensic practice, especially in early ischemia without definitive histological findings. Proteomic techniques and molecular profiling may provide complementary diagnostic information beyond conventional autopsy. : We applied an untargeted high-resolution proteomic approach to postmortem cardiac tissue samples from cardiovascular (ischemic and congestive) and non-cardiovascular deaths. Identified proteins were analyzed using bioinformatic and differential expression workflows. Selected candidates were evaluated in peripheral blood samples for translational validation using statistical modeling, including regression analyses and receiver operating characteristic (ROC) curve assessment. : A total of 572 proteins were identified. Although no proteins fulfilled strict exclusivity criteria for a single cause-of-death group, differential expression analysis revealed distinct molecular patterns distinguishing ischemic, congestive, and non-cardiovascular deaths. Thirty-one proteins were differentially expressed between ischemic and congestive cases, including α-1 antitrypsin (AAT), plasma levels did not demonstrate statistically significant discrimination. In contrast, plasma Apolipoprotein A-IV (ApoA-IV) levels were significantly associated with ischemic death in regression models, and ROC analysis yielded a cutoff point with complete separation between ischemic and selected non-cardiovascular cases. However, the limited sample size warrants cautious interpretation due to potential overfitting. : Postmortem cardiac proteomic profiling reveals biologically coherent molecular signatures associated with different cardiovascular causes of death. Although further validation in larger independent cohorts is required, ApoA-IV emerges as a promising candidate biomarker for ischemic cardiac death. Multimarker proteomic strategies may complement traditional autopsy to enhance diagnostic accuracy in forensic investigations, particularly in cases with equivocal morphological findings. - Source: PubMed
Publication date: 2026/04/16
Monedero Marina InvernónArtiago María Esther PérezDel Rincón Juan Pedro HernándezFuentes María DoloresPérez-Cárceles María DOsuna EduardoHernández-Romero Diana - Fatigue persists as a dominant and debilitating phenomenon in long-COVID, yet its underlying biological mechanisms remain unclear. While inflammatory variables tend to normalize within months post-infection, fatigue continues to significantly impact quality of life. Understanding whether specific biomarkers associate with long-COVID fatigue could shed light on pathophysiological mechanisms and potential therapeutic targets. - Source: PubMed
Publication date: 2026/03/31
Omdal RoaldLenning Ole BerntJonsson GreteKvaløy Jan TerjeSkoie Inger MarieBraut Geir SverreGrimstad Tore